[Montgomery, Ala] – The Alabama Medical Cannabis Commission (AMCC), at its meeting on December 12, 2023, ranked applicants and voted to award medical cannabis business licenses to the following integrated facility applicants.

Integrated Facility License
Trulieve AL, Inc.
Sustainable Alabama, LLC
Wagon Trail Med-Serv, LLC
Flowerwood Medical Cannabis, LLC
Specialty Medical Products of Alabama

“First, I thank all of the integrated facility applicants for their diligent efforts throughout this lengthy licensing process.  Second, I cannot emphasize strongly enough how much I appreciate the commitment and hard work of  each Commissioner as we have navigated through this phase of the program,” explained Commission Chairman Rex Vaughn. “The result of these efforts has led to the award of licenses to entities who the Commission has determined are well-suited to serve patients through Alabama’s medical cannabis program.”

Following this award of licenses, the procedural timelines associated with the post-award licensing process will begin along with the pre-issuance site inspections. Those applicants who were awarded a license will have 14 days to submit the appropriate license fee. Also, any applicant who has been denied a license has 14 days to request an investigative hearing before the Commission for reconsideration of said denial.

Under the rules promulgated by the Alabama Board of Medical Examiners, physicians may begin the certification process to recommend medical cannabis to patients after business licenses have been issued. For a patient to qualify for medical cannabis, the patient must have at least one of the qualifying conditions and be recommended for medical cannabis by a certified physician.

To learn more about the Alabama medical cannabis program visit amcc.alabama.gov.


Alabama Act 2021-450 establishes the Alabama Medical Cannabis Commission and authorizes the Commission to implement the Act by making medical cannabis derived from cannabis grown in Alabama available to registered qualified patients, by licensing facilities that process, transport, test, or dispense medical cannabis, and by administering and enforcing the Act and all rules adopted pursuant to the Act.

The Commission, per the statute, could award up to twelve (12) cultivator licenses, four (4) processor licenses, four (4) dispensary licenses, five (5) integrated facility licenses and an unspecified number of secure transport and state testing laboratory licenses.

Commission members are appointed to the commission for established terms by various appointing authorities, including the Governor, Lieutenant Governor, President Pro Tempore of the Senate, Speaker of the House of Representatives, Commissioner of Agriculture and Industries, State Health Officer, Attorney General, and Secretary of the Alabama State Law Enforcement Agency.  Each commission member represents certain segments that the legislature deemed important to the establishment and regulation of the medical cannabis program in Alabama. Members of the Commission include: Dr. William Saliski, Pulmonologist; Dr. Sam Blakemore, Pharmacist; Dwight Gamble, Banker; Dr. Angela Martin, Pediatrician; Dr. Eric Jensen, Biochemist; Loree Skelton, Attorney; Rex Vaughn, Farmer; Judge Charles Price, Circuit Judge; Taylor Hatchett, Farmer; James Harwell, Nurseryman and Landscaper, Dr. Jerzy Szflarski, Neurologist, Dr. Jimmie Harvey, Oncologist, and Dion Robinson, Department of Corrections.

Under Alabama’s program, registered certifying physicians may recommend medical cannabis to patients who have been diagnosed with autism spectrum disorder; cancer-related pain or nausea; Crohn’s Disease; depression; epilepsy or conditions causing seizures; HIV/AIDS-related nausea or weight loss; panic disorder; Parkinson’s Disease; persistent nausea; post-traumatic stress disorder (PTSD); sickle cell anemia; spasticity associated with multiple sclerosis or spinal cord injury; Tourette’s Syndrome; a terminal illness; or conditions causing chronic or intractable pain.

Medical cannabis products that may be recommended to patients include tablets, capsules, tinctures, gelatinous cubes, gels, oils or creams for topical use, suppositories, transdermal patches, nebulizers, or liquids or oils for use in an inhaler. Raw plant materials, products administered by smoking or vaping, or food products such as cookies or candies will not be allowed.